Drugs / PD1-Vaxx
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06692959 | Jun 2025 → Jun 2026 | colorectal cancer | University of Southampton | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PD1-Vaxx | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06692959 ↗ |
| Known as | IMU-201 | “IMU-201 is combined with water for Injection (WFI) and is emulsified with Montanide ISA 51 VG adjuvant to produce PD1-Vaxx.” NCT06692959 ↗ |
| Modality | Vaccine | “PD-1 vaccine IMU-201 (PD1-Vaxx)” NCT06692959 ↗ |
| Route | Intramuscular | “PD1-Vaxx intramuscularly into the deltoid region of the upper arm” NCT06692959 ↗ |